{"id":5420,"date":"2026-05-13T22:15:00","date_gmt":"2026-05-13T20:15:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=434cff6fddcb1218203f04d0a6f9a195"},"modified":"2026-05-13T22:15:00","modified_gmt":"2026-05-13T20:15:00","slug":"dyno-therapeutics-announces-expanded-frontiers-network-and-second-annual-genetic-agency-technology-conference-gatc","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=5420","title":{"rendered":"Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>Dyno Frontiers Network expands to become a curated ecosystem connecting therapeutic developers with the delivery technology, manufacturing and development services, investment and expertise they need to more confidently advance innovative genetic medicine toward the clinic<\/i><\/li>\n<li>\n<i>GATC 2026 to convene patients, AI pioneers, technologists, entrepreneurs and therapeutic developers in San Francisco on November 18 to accelerate progress toward empowering patients everywhere with genetic agency<\/i><\/li>\n<li>\n<i>New initiatives reflect Dyno\u2019s commitment to enabling gene therapy developers to bring many new gene therapies to patients and realize a future with genetic agency<\/i><\/li>\n<\/ul><p>WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of <i>in vivo<\/i> gene delivery, today announced significant updates to two mission-driven initiatives: the Dyno Frontiers Network and the annual Genetic Agency Technology Conference (GATC). Both efforts aim to accelerate progress in delivering new therapeutic options to patients in support of genetic agency \u2013 an individual\u2019s ability to take action at the genetic level to live a healthier life. Details were shared during the company\u2019s Scientific Symposium at the 29th American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260513417190\/en\/2803865\/5\/Logo-Black-R-v3.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260513417190\/en\/2803865\/22\/Logo-Black-R-v3.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260513417190\/en\/2803865\/5\/Logo-Black-R-v3.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260513417190\/en\/2803865\/21\/Logo-Black-R-v3.jpg\" \/><\/a><p>\n\u201cThe Frontiers Network and GATC both exist because getting transformative therapeutic options to patients is hard, and most developers can't do it without trusted partners. At Dyno we\u2019ve established ourselves by building the AI-powered design and delivery technology developers can build on, and our latest efforts show how we\u2019re scaling beyond that,\u201d said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno. \u201cThrough Frontiers, we're making it easier for entrepreneurs, patients, and their advocates to bring genetic medicines toward the clinic more efficiently and with reduced development challenges. Through GATC, we're building a community around a shared purpose: motivating partnership and progress toward a world where patients everywhere are empowered with genetic agency.\u201d<\/p><p>\n<b>Expanding the Dyno Frontiers Network<\/b><\/p><p>\nThe Dyno Frontiers Program has evolved into the Dyno Frontiers Network, a curated ecosystem connecting therapeutic developers advancing innovative payloads \u2013 including base and prime editors, epigenetic editors, trans-splicing constructs, vectorized antibodies and tissue-specific synthetic promoters \u2013 with the capsid technology, manufacturing expertise, development services and investment capital they need to move their programs forward with more confidence.<\/p><p>\nThe Dyno Frontiers Program was originally launched in <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dynotx.com%2Fnews%2Fdyno-therapeutics-announces-inaugural-2025-genetic-agency-technology-conference-and-launch-of-dyno-frontiers-program-to-accelerate-progress-in-patient-empowering-gene-therapies&amp;esheet=54535068&amp;newsitemid=20260513417190&amp;lan=en-US&amp;anchor=May+2025&amp;index=1&amp;md5=c66b7145bf34688891fe3748eadeb35e\" rel=\"nofollow\" shape=\"rect\">May 2025<\/a> to give therapeutic developers access to Dyno\u2019s AI-designed AAV capsid technology. In <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dynotx.com%2Fnews%2Fdyno-therapeutics-and-trisk-bio-announce-strategic-manufacturing-partnership-through-expanded-frontiers-program&amp;esheet=54535068&amp;newsitemid=20260513417190&amp;lan=en-US&amp;anchor=November+2025&amp;index=2&amp;md5=d076cca19c02c0c5dfe022f86cd12c84\" rel=\"nofollow\" shape=\"rect\">November 2025<\/a>, Frontiers added its first manufacturing partner, Trisk Bio, bringing scalable AAV production into the network. With the addition of capable manufacturers, contract research organizations (CROs), regulatory consultants with AAV gene therapy expertise and investors, the Network now offers developers more partners to choose from as they journey to the clinic.<\/p><p>\nThe Frontiers Network currently comprises 15 therapeutic developers, seven manufacturers, six service providers, and 15 investor partners. The Network\u2019s unique structure enables any member to partner directly with one another without Dyno as an intermediary. This design choice creates both a marketplace where partners compete for developers' business, and a community where they collaborate to help developers succeed and, ultimately, enable new genetic medicine options. These partners include:<\/p><ul class=\"bwlistdisc\">\n<li>\nManufacturing: 3PBiovian, Andelyn Biosciences, Cirsium Biosciences, Franklin Biolabs, PackGene, Revvity and Trisk Bio<\/li>\n<li>\nServices: Aldevron, BioAnalysis LLC, Charles River Laboratories, Curi Bio, Dark Horse Consulting Group and Eliquent Life Sciences<\/li>\n<li>\nInvestors: a16z, Biotech Funding Portal, CRV, Curie.Bio, Dimension, GV, Insight Partners, KdT Ventures, Lux Capital, Obvious Ventures, Pier Three Capital, Pillar VC, Polaris Partners, Vibe Bio and for companies incubating in Y Combinator<\/li>\n<\/ul><p>\n\u201cDyno\u2019s approach has always been about supporting the development of new therapies by addressing key obstacles developers face,\u201d said Tyson Bertmaring, MBA, Head of Partnership Success. \u201cThe Frontiers Network is a product of our conviction that when competition and collaboration co-exist, progress accelerates. By aligning incentives across every participant in the network, we turn shared progress into shared success, bringing the world closer to a future with genetic agency for all.\u201d<\/p><p>\nLearn more about the Frontiers Network at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fdynotx.com%2Ffrontiers-network&amp;esheet=54535068&amp;newsitemid=20260513417190&amp;lan=en-US&amp;anchor=dynotx.com%2Ffrontiers-network&amp;index=3&amp;md5=72b5a8177e787cf8660c2ee5d050461c\" rel=\"nofollow\" shape=\"rect\">dynotx.com\/frontiers-network<\/a> or contact <a  href=\"mailto:partnerwith@dynotx.com\" rel=\"nofollow\" shape=\"rect\">partnerwith@dynotx.com<\/a>.<\/p><p>\n<b>Announcing GATC 2026<\/b><\/p><p>\nDyno also announced its second annual Genetic Agency Technology Conference (GATC) will take place November 18, 2026 in San Francisco. Last year's inaugural conference convened 200 patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers to advance the field of genetic medicine. GATC 2026 builds on that momentum, bringing together leading voices to address the scientific, technical, and translational challenges standing between today's advances and treatments patients can access. Topics will include patient stories, AI for sequence design and therapeutic development, frontier genetic technologies, along with challenges and opportunities in preclinical development, manufacturing and regulatory pathways.<\/p><p>\nThe first cohort of featured speakers all have a personal connection to genetic agency, including:<\/p><ul class=\"bwlistdisc\">\n<li>\nAlex Lenail, Ph.D., Postdoctoral Researcher at the Wyss Institute, Harvard Medical School\n<ul class=\"bwlistcircle\">\n<li>\nHis father's adrenoleukodystrophy (ALD) diagnosis and the shelving of its only treatment set Alex on a mission to develop a gene therapy.<\/li>\n<\/ul><\/li>\n<li>\nAndreas Borg, Founder at CURE5 Foundation and Full Stack Engineer at Jimini Health\n<ul class=\"bwlistcircle\">\n<li>\nCo-founded CURE5 Foundation after his daughter was diagnosed with CDKL5 Deficiency Disorder, and is applying his software engineering background to build AI tools that help families make decisions and accelerate therapeutic development.<\/li>\n<\/ul><\/li>\n<li>\nDean Suhr, President &amp; Cofounder at MLD Foundation\n<ul class=\"bwlistcircle\">\n<li>\nAfter two daughters were diagnosed with metachromatic leukodystrophy (MLD) in 1995, Dean co-founded the MLD Foundation, partnered with researchers to bring gene therapy Lenmeldy to FDA approval in 2024, and fought in parallel to add MLD to newborn screening.<\/li>\n<\/ul><\/li>\n<li>\nHeidi Epstein, Vice Chair at Rett Syndrome Research Trust and Founder of Reverse Rett LA\n<ul class=\"bwlistcircle\">\n<li>\nWhen her 3-year-old daughter Hannah was diagnosed with Rett syndrome in 2008, she was told a cure was impossible. Undeterred, Heidi joined the board of the Rett Syndrome Research Trust and founded Reverse Rett LA, now the world's largest Rett syndrome fundraiser. The event has played a critical role in helping to advance the field from basic science to two ongoing gene therapy trials.<\/li>\n<\/ul><\/li>\n<li>\nLinde Jacobs, Registered Nurse and Frontotemporal Dementia (FTD) Caregiver Advocate\n<ul class=\"bwlistcircle\">\n<li>\nAfter caring for and losing her mother to early-onset FTD-MAPT and facing the same inherited fate for herself and many in her family, Linde is racing to advance a gene therapy before the next generation is impacted.<\/li>\n<\/ul><\/li>\n<li>\nMatt Wilsey, CEO at Grace Science, LLC\n<ul class=\"bwlistcircle\">\n<li>\nFounded Grace Science after his daughter's NGLY1 deficiency diagnosis and advanced the disease\u2019s first gene therapy into the clinic, treated his daughter in 2025 as part of a clinical program.<\/li>\n<\/ul><\/li>\n<li>\nStevie Ringel, Founder &amp; CEO at Nome, President at Kizuna Foundation\n<ul class=\"bwlistcircle\">\n<li>\nFacing blindness from an ultra-rare KIZ gene mutation shared with his sister, Stevie founded Kizuna Foundation to develop a gene therapy to save their sight, and launched Nome.bio to use AI to make personalized therapeutics accessible to any rare disease family.<\/li>\n<\/ul><\/li>\n<\/ul><p>\nLearn more about GATC 2026 and apply to attend at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dynotx.com%2Fgatc2026&amp;esheet=54535068&amp;newsitemid=20260513417190&amp;lan=en-US&amp;anchor=dynotx.com%2Fgatc2026&amp;index=4&amp;md5=5f0cfafc57c05a69a8ff6222d9fe3283\" rel=\"nofollow\" shape=\"rect\">dynotx.com\/gatc2026<\/a>.<\/p><p>\n<b>About Dyno Therapeutics<\/b><\/p><p>\nDyno Therapeutics is on a mission to build high-performance genetic technologies that transform patients\u2019 lives. Dyno applies AI to build technologies for gene delivery and sequence design that advance \u201cGenetic Agency\u201d \u2013 an individual's ability to take action at the genetic level to live a healthier life \u2013 through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput <i>in vivo<\/i> experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications including eye, muscle and CNS. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including through strategic collaborations with leading gene therapy developers Astellas and Roche and with technology companies including NVIDIA. Dyno's AI-designed capsids are available for direct licensing and through the Dyno Frontiers Network. Visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dynotx.com&amp;esheet=54535068&amp;newsitemid=20260513417190&amp;lan=en-US&amp;anchor=www.dynotx.com&amp;index=5&amp;md5=31d247f587aba022e2c3c1e6cee4a132\" rel=\"nofollow\" shape=\"rect\">www.dynotx.com<\/a> for more information.<\/p><p>\n\u2018Dyno Therapeutics\u2019, \u2018dyno\u2019, the Dyno logo, and mountain logo are registered trademarks of Dyno Therapeutics, Inc. All rights reserved.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contact:<\/b><br\/>Thermal for Dyno Therapeutics\n<br\/><a  href=\"mailto:dynotx@thermalpr.com\" rel=\"nofollow\" shape=\"rect\">dynotx@thermalpr.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dyno Frontiers Network expands to become a curated ecosystem connecting therapeutic developers with the delivery technology, manufacturing and development services, investment and expertise they need to more confidently advance innovative genetic med&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5420","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5420"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5420\/revisions"}],"predecessor-version":[{"id":5421,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5420\/revisions\/5421"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}